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Abstract
Introduction: The aim of the present study was to examine how weight loss treatment modulates plasma concentrations of ghrelin and
insulin-like growth factor 1 (IGF-1) in obese women and to determine whether there is any association with possible changes in plasma
concentrations of these hormones after weight loss.
Material and methods: The study group consisted of 22 obese women without additional disease (age 40.6 ± 12.9 years; BMI 37.2 ± 4.6 kg/m2).
All subjects participated in a 3-month weight reduction program. The measurements were performed at baseline and after weight loss.
Plasma concentration of ghrelin and IGF-1 were measured by enzyme – linked immunosorbent assay (ELISA) kit. Serum concentrations of
insulin were measured by radioimmunoassay (RIA). Body composition was determined by bioelectrical impedance analysis using a Body-
stat analyser.
Results: The mean weight loss was 9.3 ± 4.1 kg (9.7 ± 4.3%). Following weight loss, plasma ghrelin and IGF-1 concentrations increased
significantly (63.5 ± 13.0 vs. 72.8 ± 15.1 pg/ml; p < 0.01; 126.9 ± 67.0 vs. 170.5 ± 83.3 ng/ml p < 0.01, respectively) and serum insulin
concentrations decreased significantly (17.5 ± 8.5 vs. 14.8 ± 10.4 mIU/ml p< 0.05). We observed a significant positive correlation between
the increase of ghrelin and decrease of body fat percentage after weight loss (r = 0.44, p = 0.03). There are no correlations between change
of ghrelin and IGF-1concentrations and between changes of insulin and IGF 1 concentrations.
Conclusion: Plasma concentrations of ghrelin and IGF-1 increased after weight loss. However, it seems there is no association between
serum concentrations of ghrelin and IGF-1 in obese women. (Pol J Endocrinol 2008; 59 (4): 301–304)
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Streszczenie
Wstęp: Celem pracy była ocena wpływu redukcji masy ciała na stężenie w osoczu otyłych kobiet greliny i insulinopodobnego czynnika
wzrostu 1 (IGF-1) oraz określenie czy występuje związek między ewentualnymi zmianami tych związków podczas redukcji masy ciała.
Materiał i metody: Grupa badana składała się z 22 otyłych kobiet bez chorób towarzyszących (wiek 40,6 ± 12,9 lat; BMI 37,2 ± 4,6 kg/m2).
Wszystkie badane uczestniczyły w 3-miesięcznej kompleksowej grupowej kuracji odchudzającej. Pomiarów dokonano przed i po reduk-
cji masy ciała. Stężenie greliny i IGF-1 w osoczu oznaczono metodą immunoenzymatyczną (ELISA). Stężenie w surowicy insulin oznaczo-
no metodą radioimmunologiczną (RIA). Skład ciała oceniono metodą bioimpedancji z użyciem aparatu Bodystat.
Wyniki: Średnia redukcja masy ciała wynosiła 9,3 ± 4,1 kg (9,7 ± 4,3%). Stężenie greliny i IGF-1 w osoczu istotnie wzrosło (odpowiednio
63,5 ± 13,0 vs. 72,8 ± 15,1 pg/ml; p < 0,01; 126,9 ± 67,0 vs. 170,5 ± 83,3 ng/ml; p < 0,01), natomiast stężenie insulin obniżyło się istotnie
(17,5 ± 8,5 vs. 14,8 ± 10,4 mIU/ml p < 0,05). Zaobserwowano istotne dodatnie korelacje między wzrostem stężenia greliny i obniżeniem się
procentowej zawartości tłuszczu (r = 0,44, p = 0,03). Nie występowały korelacje między zmianami stężeń greliny a IGF-1 oraz między
zmianami stężeń insulin a IGF-1.
Wnioski: Redukcja masy ciała powoduje wzrost stężenia w osoczu greliny i IGF-1. Wydaje się jednak, że nie występuje związek między
zmianami stężeń greliny i IGF-1 u otyłych kobiet. (Endokrynol Pol 2008; 59 (4): 301–304)
Słowa kluczowe: otyłość, grelina, IGF-1, redukcja masy ciała
Introduction
It has been shown that growth hormone secretion is ne-
gatively and independently associated with age and adi-
posity in humans [1]. Circulating GH levels are also de-
creased in obesity [2]. Therefore, it seems that obesity is
a real condition of GH insufficiency [3] despite which
(IGF-1) levels are reported as low normal or normal [4–7].
However, some studies revealed decreased IGF-1 levels
in obese adults [8] or increased IGF-1 levels in obese chil-
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dren [9]. Kaytor et al. [10] suggested that lack of decrease
of IGF-1 production might be an effect of the augmen-
ted action of insulin on intracellular GH signalling.
The peptide hormone ghrelin is predominantly pro-
duced by the stomach. However, its expression has also
been demonstrated in other tissues such as bowels, pan-
creas, kidneys, placenta, gonads, pituitary, hypothala-
mus and adipose tissue [11–13].
The mechanism of ghrelin action on GH secretion is
mainly dependent on the interaction between GH–re-
leasing hormone, ghrelin and somatostatin [14–16].
The circulating ghrelin level is increased in anore-
xia and cachexia but is reduced in obesity [17–19]. Pre-
viously we observed an increase in plasma concentra-
tions of ghrelin after weight loss in obese women [20].
Our previous observations [21] and data from lite-
rature seem to suggest that ghrelin may be regarded as
a new factor influencing GH secretion [22]. On the ba-
sis of data from literature [23] and on our previous stu-
dies [20, 21], we hypothesised that weight loss may
modulate the secretion of IGF-1, and that ghrelin may
be one of the factors participating in this process.
 The aim of the present study was to examine how
weight loss modulates plasma concentrations of ghrelin
and IGF-1 in obese women and to determine whether
there is any association with possible changes in plasma
concentrations of these hormones after weight loss.
Material and methods
The study group consisted of 22 obese women, age 40.6 ±
± 12.9 years, weight 97.0 ± 15.5 kg, body mass index
(BMI) 37.2 ± 4.6 kg/m2. The characteristics of the study
group are listed in Table I.
All obese subjects included in the study were dia-
gnosed as having simple obesity without additional di-
seases. All patients had serum concentrations of gluco-
se and insulin within the reference range. The exclusion
criteria included: evidence of present or recent (prece-
ding 3 months) infectious disease, fever or drug therapy.
The study was conducted after obtaining informed
consent from all the subjects. The study was approved
by the Local Ethical Committee.
All obese patients participated in a 3-month weight
reduction program that consisted of 1) a group instruc-
tion in behavioural and dietary methods of weight con-
trol carried out every two weeks, 2) 1000–1400 kcal/day
balanced diet, and 3) physical exercises 30–40 min/day.
The measurements were performed at the baseline
and after the 3-month program. Body weight and he-
ight were measured, and body mass index (BMI) calcu-
lated as weight in kilograms divided by the square of
the height in metres. Body composition was determi-
ned by impedance analysis using a Bodystat analyser.
Six to eight ml samples of venous blood were collec-
ted in the morning, following an overnight fast. The
blood samples were collected according to the recom-
mendations of the kit manufacturers. The blood for me-
asurements both of ghrelin and IGF was collected into
Lavender Vacutainer tubes containing EDTA. Then the
Lavender Vacutainer tubes were gently rocked several
times immediately after collection of blood for anti-co-
agulation. Next the blood was transferred from the La-
vender Vacutainer tubes to centrifuge tubes containing
aprotinin (0.6 TIU/ml of blood) and was gently rocked
several times to inhibit the activity of proteinases. The
plasma was collected after centrifugation of the blood
at 1600 ¥ g for 15 minutes at 4°C .
 The obtained plasma was drawn into plastic vials
and stored at –80°C until the time of assay.
Insulin was determined by radioimmunoassay
(RIA); (DPC Diagnostic Products Corporation, USA).
The plasma ghrelin was measured using a commer-
cially available, highly sensitive, enzyme-linked immuno-
sorbent assay (ELISA) kit (Phoenix Pharmaceuticals, USA)
The sensitivity of the ghrelin assay is, according to
the manufacturer’s range, less than 6.0 pg/ml. Mean
intra-assay coefficient of variance was < 6.0%, and mean
interassay coefficient of variance was < 9.0%.
Plasma IGF-1 was measured using a commercially
available, highly sensitive , enzyme-linked immunosor-
bent assay (ELISA) kit (R&D Systems, USA).
The sensitivity of the IGF 1assay is typically less than
0.026 ng/ml. Mean intra-assay coefficient of variance was
< 4.5%, and mean interassay coefficient of variance was
< 8.5%.
Statistical analysis
All text and table values are expressed as mean ± SD.
Changes from baseline in anthropometrics values and
hormone levels were evaluated using paired t-test. The
Table I. Patient characteristics and the effect of weight
reduction treatment
Tabela I. Charakterystyka chorych i efekty terapii odchudza-
jącej
Baseline After weight loss p
(mean ± SD) (mean ± SD)
Weight [kg] 97.0 ± 15.5 87.4 ± 15.0 0.001
BMI [kg/m2]  37.2 ± 4.6  33.7 ± 4.6 0.001
Body fat [kg]  42.4 ± 13.8 36.5 ± 10.0 0.01
Body fat (%)  42.8 ± 9.6  41.3 ± 6.4 NS
Fat-free mass [kg]  54.6 ± 8.0  50.9 ± 6.6 0.05
Fat-free mass (%)  57.2 ± 9.4  58.7 ± 6.7 NS
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relationships between changes in fasting plasma ghre-
lin levels and changes in IGF-1 levels and body compo-
sition following weight loss were examined by Pear-
son’s correlation analysis. Stepwise multivariate analy-
sis was performed with plasma levels of ghrelin, Dgh-
relin, IGF-1 and DIGF-1 as the dependent variables.
A value p < 0.05 was considered statistically significant.
Results
The effects of weight loss treatment are presented in
Table I. Mean weight loss was 9.3 ± 4.1 kg. BMI decre-
ased from 37.2 ± 4.6 at the baseline to 33.7 ± 4.6 after
treatment. Some significant differences in body com-
position were also found. The body weight reduction
treatment led to a significant decrease of body fat abso-
lute (p = 0.01), which was accompanied by a moderate
decrease of fat-free mass absolute (p = 0.05).
In obese subjects, ghrelin levels (p < 0.01) and IGF-1
levels (p < 0.01) increased significantly following we-
ight loss (Table II). Serum concentrations of insulin de-
creased significantly (p < 0.05) after treatment.
Ghrelin and IGF-1 did not show any correlation with
age, weight, BMI and percentage of body fat, or serum
concentrations of insulin. However, a significant posi-
tive correlation was found between serum concentra-
tions of insulin and BMI (r = 0.54; p = 0.01) and a nega-
tive correlation was found between serum concentra-
tions of insulin and fat-free mass (r = –0.47; p = 0.03)
before treatment.
We did not observe any correlation between Dgh-
relin and DIGF-1 or between DIGF-1 and DBMI, D body
mass, Dbody fat absolute and percentage, and serum
concentration of insulin. However, there was a positi-
ve correlation between Dghrelin and Dbody fat (%)
(r = 0.44, p = 0.03).
We performed stepwise multivariate regression ana-
lysis using ghrelin, Dghrelin, GH and DGH as depen-
dent variables. The Dghrelin was related negatively to
Dbody fat (kg) (r = 0.26; F = 11.2; p = 0.001) and Dbody
fat (%) (r = 0.23; F = 14.2; p = 0.002). Models were fit-
ted to assess the role of age, BMI, body fat (kg and %),
Dbody fat (kg and %), fat-free mass (kg and %), and
Dfat-free mass (kg and %). Analysis of the remaining
regression coefficients did not reveal any significant
differences.
Discussion
As described above, the effect of obesity on the produc-
tion and serum concentrations of insulin–like growth
factor 1 is unclear [4–9]; the IGF-1 serum concentrations
increased after weight loss [23] Experimental studies
suggest that endogenous ghrelin may constitute part
of a pathway involved in modulating the GH/IGF-1
pathway in response to changes in nutrient availabili-
ty, such as those induced by a high-fat diet [24]. Some
recent studies have shown that ghrelin, the endogeno-
us ligand of the GH secretagogue receptors, is down-
regulated in human obesity [17, 25].
 In our previous study [20, 21] and in other authors’
studies [26], increased circulating levels of ghrelin after
weight loss were observed; therefore, we speculate that
ghrelin may be one of the factors which increases IGF-1
release after weight reduction.
 In the present study, as previously reported in our
studies [20, 21], we observed increased plasma concen-
trations of ghrelin after weight loss and negative correla-
tions between changes of body fat and changes of ghre-
lin. This result is also in accordance with other authors’
observations [27]. We also observed a significant incre-
ase of IGF-1 after weight loss. These findings are in ac-
cordance with results obtained by Rasmussen et al. [23]
and by Engström et al [28]. Additionally, Rasmussen et
al. [23] suggested, on the basis of their findings, that chan-
ges in plasma concentrations of IGF-1 are independent
of changes in growth hormone after weight reduction.
However, we did not observe correlations between pla-
sma concentrations of ghrelin and IGF-1 before and after
weight loss, or between changes of these parameters after
weight loss. Therefore, it seems that ghrelin is not the
factor employed in the increase of circulating IGF-1 le-
vels after weight loss. Previous studies revealed that in-
sulin might be a factor participating in stimulation of pro-
duction of IGF-1 in obese women [10]. However, we did
not observe correlations between serum concentrations
of insulin and plasma concentrations of IGF-1, or betwe-
en changes of these parameters. It seems that there are
some limitations in the interpretation of the obtained
results; we measured total plasma ghrelin concentrations,
as it is already known that pro-ghrelin cleavage may ge-
nerate another peptide obestatin with the opposite phy-
siological action to ghrelin [29]. Further studies are ne-
cessary to clarify which factors participate in changes of
IGF-1 production after weight loss.
Table II. Plasma concentrations of ghrelin, growth hormone
and insulin
Tabela II. Osoczowe stężenie greliny, hormonu wzrostu
i insuliny
Baseline After weight loss p
(mean ± SD)  (mean ± SD)
Ghrelin [pg/ml] 63.5 ± 13.0  72.8 ± 15.1 0.01
IGF-1 [ng/ml]  126.9 ± 67.0  170.5 ± 83.3 0.01
Insulin [mIU/ml] 17.7 ± 8.5  14.8 ± 10.4 0.05
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Conclusions
Plasma concentrations of ghrelin and IGF-1 increased
after weight loss. However, it seems that there is no as-
sociation between plasma concentrations of ghrelin and
IGF-1 in obese women.
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